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Medicines are licensed for use in humans by regulatory authorities. The concept of licensing is that it 
helps ensure that medicines are safe, effective and of an adequate quality for regular use. [1] 
Licensing was introduced due to concerns about safety not to ensure that medicines are effective. It 
was a response to specific examples of drug toxicity,notably the grey baby syndrome in neonates 
following the use of the antibiotic chloramphenicol and phocomelia in the developing foetus 
following ingestion of thalidomide by pregnant women. [2] Within the UK, the Medicines Act was 
passed in 1968. The licensing of medicines is both a control on products of public interest as well as 
an authorisation to sell for pharmaceutical companies. Pharmaceutical companies are only allowed 
to promote licensed medicines. Prescribers, however, are free to prescribe the most appropriate 
medicine for their patient. This should be based on the best available scientific evidence. Medicines 
can be licensed (authorised) by either national regulatory agencies (national route) or the European 
Medicines Agency (centralised route). It is only once they are licensed, that they can be marketed 
and made available to patients. [1] 
 
Off-label use 
In the late 90’s, there were several studies documenting the extent of off-label and unlicensed use of 
medicines in paediatric in-patients. [3] These studies highlighted that many medicines used in 
paediatric patients are off-label, i.e. used in a manner different to that recommended in the product 
license. Off-label use may relate to use at a different dose or frequency, by a different route, or in a 
different age group for that which is authorised. Additionally, medicines may also be used for 
different indications to those contained within the product license. Following the initial studies 
within the UK, there were studies involving different European countries and subsequently countries 
outside of Europe. [3] These studies all showed that off-label drug use was common in paediatric 
patients both in hospital and in the community. This off-label use can  increase the possibility of an 
adverse drug reaction occurring [2]. 
In response to the widespread concern regarding the extensive off-label use of medicines in the 
paediatric population, legislation was passed both in Europe and North America to encourage 
pharmaceutical companies to study clinically required medications within the paediatric population. 
[4] Since this legislation was introduced, numerous studies have continued to be performed in 
different countries around the world documenting off-label drug use. Off label drug use in paediatric 
patients, however, is already well documented. Further studies of off label drug prevalence 
utilisation are not currently needed, whereas we do need appropriate comparative studies  
evaluating the safety and efficacy of off-label vs on-label drugs. 
 
Evidence based prescribing 
One of the major concerns regarding off-label use, in particular in paediatric patients, was not that 
medicines were unauthorised but rather there was an insufficient evidence base for the use of many 
medicines in children. It was the lack of an evidence base that most concerned health professionals 
specifically interested in this problem. [5] Evidence based medicine had become accepted with adult 
patients and the concern was that paediatric patients were being ignored. The evidence based 
practice of prescribing medicines appropriately is increasingly being recognised as a major issue, not 
only in low and lower-middle income countries but also in upper-middle and high income countries.  
 
The importance of evidence based medicine is highlighted by the paper by De Bruyne, which looks at 
first generation antihistamines. [6] They highlight that although these medicines are licensed, there 
is a large variability in labelled indications and licensing ages in different countries in Europe. This   
raises questions concerning the regulatory process.  The same available data has been evaluated 
differently by different countries. Additionally, the evidence basis for the use of medicines in these 
indications is questionable. The first generation antihistamines were licensed a long time ago. One 
would anticipate that the requirements for licensing are more thorough now than previously. 
However, it is important to recognise however that for a medicine to be licensed, one only has to 
show that it is more effective than placebo. The lack of a requirement for studies comparing the new 
drug to established treatment has been raised as a major weakness of the European regulatory 
process. [1]   It has been suggested that evaluating “added therapeutic value” should be added to 
the current criteria for drug evaluation of quality, efficacy and safety. [1] 
 
The main message of the paper is that it is the evidence base for the use of medicine for a specific 
disease that is the most important issue. Knowledge must guide the medical decisions and not the 
marketing status (licence). Researchers should stop studying the epidemiology of off-label drug use 
in children. Their independent research would have a far greater impact if they studied the evidence 
basis for many current practices in prescribing and also whether medicines are prescribed rationally 
or not. For their part, medicines agencies must put patients’ and public health services’ interest first 
with more determination. [1] 
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